Correction: Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study)

Affiliations

¹ Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, Italy.
² Department of Infectious Diseases, Unit of Geriatric Infectious Diseases, AORN Ospedali Dei Colli, Cotugno Hospital, Naples, Italy. agnesegiaccone94@gmail.com.

Published Erratum

Ivan Gentile et al. BMC Infect Dis. 2025.

. 2025 Apr 29;25(1):633.

doi: 10.1186/s12879-025-11043-w.

¹ Department of Clinical Medicine and Surgery, Section of Infectious Diseases, University of Naples Federico II, Naples, Italy.
² Department of Infectious Diseases, Unit of Geriatric Infectious Diseases, AORN Ospedali Dei Colli, Cotugno Hospital, Naples, Italy. agnesegiaccone94@gmail.com.

No abstract available

Erratum for

Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study).
Gentile I, Giaccone A, Scirocco MM, Di Brizzi F, Cuccurullo F, Silvitelli M, Ametrano L, Alfè FA, Pietroluongo D, Irace I, Chiariello M, De Felice N, Severino S, Viceconte G, Schiano Moriello N, Maraolo AE, Buonomo AR, Scotto R; Federico II COVID team. Gentile I, et al. BMC Infect Dis. 2024 Dec 18;24(1):1434. doi: 10.1186/s12879-024-10303-5. BMC Infect Dis. 2024. PMID: 39696011 Free PMC article.

1. Gentile I, et al. Efficacy of Nirmatrelvir/ritonavir in reducing the risk of severe outcome in patients with SARS-CoV-2 infection: a real-life full-matched case-control study (SAVALO Study). BMC Infect Dis. 2024;24:1434. 10.1186/s12879-024-10303-5. - PMC - PubMed